Table II.

Gene mutations of patients with pulmonary carcinoids from our cohort.

Case	Histology	Gene	AA change	Mutation type	Frequency (%)
1	TC	JAK2	K1030R	Missense variant	50.60
		KIT	A755T	Missense variant	50.40
		RB1	F198L	Missense variant	9.23
		NF1	S1100T	Missense variant	2.24
2	TC	TSC2	R57H	Missense variant	4.33
		TSC1	S1038R	Missense variant	3.12
		TSC1	S1039G	Missense variant	3.08
		ERBB4	R1155a	Nonsense variant	2.51
		NOTCH1	E242K	Missense variant	2.26
		KIT	P37S?	Frameshift variant	2.09
3	TC	ERBB4	I944V	Missense variant	35.80
		MAP2K1	D67N	Missense variant	2.89
		PDGFRA	R293H	Missense variant	2.56
		ERBB2	R47H	Missense variant	2.29
		MET	R988C	Missense variant	1.68
		EGFR	NA	Splice donor variant	1.15
4	TC	PTCH1	K251T	Missense variant	49.00
		IGF1R	G8R	Missense variant	2.65
5	TC	MET	V1088M	Missense variant	41.30
		KDR	A532V	Missense variant	2.35
6	AC	SMO	P743T	Missense variant	47.50
		CDK6	I159K	Missense variant	7.72
		IGF1R	P1290L	Missense variant	4.38
		FGFR1	DDDD163D	Deletion variant	4.15
		FGFR2	L192	Deletion variant	3.56
		IGF1R	S1180F	Missense variant	2.63
		CDK4	V281E	Missense variant	2.06

TC, typical carcinoid; AC, atypical carcinoid; AA, amino acid

^atermination codon which signals the end of translation.